Compare Gilead Sciences, Inc. (GILD) vs Zillow Group Inc Class C (Z) Price & Performance

Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.

The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.

Zillow Group (Z) trades at $33.63, up 5.56% today, amid a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with revenue growing to $2.58B in 2025 and a return to profitability with net income of $23M, though margins remain thin. However, the stock faces significant headwinds from multiple securities fraud class action lawsuits filed in July 2026, alleging misconduct related to an anticompetitive agreement.

The outlook is cautious; while analyst consensus targets $57.67 implying substantial upside, legal risks and a high P/E ratio of 135.38 pose challenges. Investors should weigh the strong revenue growth and bullish technicals against the overhang of litigation and elevated valuation before considering a position.